SMAD1 and central nervous system cancer: Overexpression of FSTL1 has been identified as an indicator of an unfavorable prognosis in GBM patients [19], with research indicating that Fstl1 stimulates glioma growth via the BMP4/Smad1/5/8 signaling pathway [9].